Phaseline

Targets › GRP78

GRP78 (Endoplasmic reticulum chaperone BiP): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Endoplasmic reticulum chaperone that plays a key role in protein folding and quality control in the endoplasmic reticulum lumen. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10/ERdj5, probably to facilitate the release of DNAJC10/ERdj5 from its substrate (By similarity). (UniProt, P11021)

Open in Phaseline: the race on GRP78, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bold TherapeuticsBOLD-100
GRP78 expression inhibitor
GRP78Phase 1Colorectal CancerJul 2027

Conditions

Colorectal Cancer (1)

Modalities

–

Companies

Bold Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.